Lead · Industry
VIG Partners builds new Korean aesthetics major, LYV Sciences
A private-equity roll-up creates a full-portfolio Korean supplier of filler, biostimulator and toxin, aimed at the US and Europe.
Korean private equity firm VIG Partners has merged LG Chem's aesthetics business (bought for roughly 200 billion won, about $144M), thread-lift maker Ultra V, and botulinum toxin developer ATGC into a single new company, LYV Sciences, unveiled around June 20, 2026 at the LINK Global symposium in Seoul. The point of stitching those three together is a vertically integrated supplier that sells across the categories most clinics buy weekly: HA fillers (the YVOIRE line, already in 45-plus countries), biostimulators (ULTRACOL, a PDO-microsphere product registered in 30-plus countries), and toxin (ATGC-110, branded Botaluma).
